Wrapping up an incredible #CSLATAM2025 💙 The energy, organization, and leadership made this symposium unforgettable. 👏🏼 Inspired by days full of learning, teamwork, and innovation. #CShockLATAM25 #TecSalud

Wrapping up two inspiring days in Cancun at the 3rd Cardiogenic Shock LATAM Symposium! An incredible gathering dedicated to one of cardiovascular care’s greatest challenges. Grateful to our speakers & participants for driving collaboration, innovation, and progress in CS

Thank you @vicentejmzmd, Dr. Guillermo Torre & #CShockLATAM25 team for the opportunity to present & moderate. High level content in an intimate, interactive setting - congrats on a great #CardiogenicShock meeting!

✨Today’s #CSLATAM2025 session on MCS highlights: 🔹 Smaller, stronger devices under FDA review 🔹 ECMO: no proven survival benefit, but role in select cases 🔹 LV unloading & VADs driving HF care 🔹 The era of MCS innovation is here 🚀 @vicentejmzmd @Babar_Basir @JHMontfort10

Kicking off Day 2 at #CShockLATAM2025 with impactful clinical cases! 🚨 Key takeaways: 🔹 Early, individualized tMCS initiation 🔹 Weigh ischemic vs bleeding risks 🔹 Multidisciplinary care is key! @UChicagoMed @TecSaludMX @vicentejmzmd

A perfect mix of science and insightful knowledge. Great people, an inspiring location, and top-notch organization. #CShockLATAM25 Excited to be part of 2026!

Another day of Shock talks. Excited to talk about my passion myocardial recovery and positive remodeling. #latamcs2025

Discussing insights about Valvular Shock in #CShockLATAM25🫀 @vicentejmzmd @JumeanMarwan @TecCardiology

🚨 #CShockLATAM25 Module 3: Pulmonary Embolism + CS 🫀 “PE may be acute, but the clot rarely is” – @SripalBangalore ⚡ Takeaways: Multidisciplinary care, PERT Teams & early recognition saves lives! 🔑 Novel modalities on PE therapy 💎 Normotensive PE!

Second Panel on #CShockLATAM25: HF CS! 🫀 👉🏻 Great clinical case of AHF by @Jorgeheartshock 👉🏻 Key clues for identifying Bi-V CS by Dr. Guilherme Olveira 👉🏻 CS in women: sex-specific differences in CS by Dr Manreet Kanwar Keeping it up with amazing lectures! #CShockLATAM2025

Great first speaker at Cardiogenic Shock LATAM! @SandeepNathanMD on Current Management of CS-AMI 🫀 👉 Rapid reperfusion & early recognition matter 👉 Vasopressors + pMCS tailored to patient 👉 Avoid bleeding/vascular complications 👉 Shock teams & system-based care

Kicking off the 3rd Annual Cardiogenic Shock LATAM Symposium! 🫀 Always a pleasure to learn and share with such amazing colleagues! @vicentejmzmd @rennquevedo @IbarrolaJC @TecCardiology #Cardiology #CardiogenicShock

Time for a refresher on vasoactive medications in #CardiogenicShock. 💊 @vicentejmzmd shares. #SCAISHOCK

🔴Asundexian versus Apixaban in Patients with Atrial Fibrillation #OCEANIC-AF 👥14810 with atrial fibrillation at risk for stroke ⏰over 11 months 🌏. 👉Asundexian 50 mg once daily was inferior for prevention of stroke and systemic embolism 🆚 Apixaban 📍The majority of

Next stop, London! 🇬🇧💂🏻‍♂️ See you at #PCRLV @PCRonline @TecCardiology @cardiotecdemty

Remarkable presentations about state-of-the-art techniques for AFib management with Dr. Valderrabano 🇺🇸 and Dr. Essebag 🇨🇦 @MiguelVldrbno @mauricioca4321

Great experience at #ACCLatam! Happy to connect with Latam cardiology community! @IbarrolaJC @TecCardiology @ACCinTouch

3er pilar del tto de ICFEp: FINERENONA El FINEARTS-HF muestra: - ⬇️ 16% ☠️CV + 🏥IC - ⬇️. 18% 🏥IC En 3 años hemos encontrado 3 grupos farmacológicos para una enfermedad q hasta entonces era huérfana. Buenas noticias sobre todo para los pacientes

Colchicine in acutely decompensated heart failure: the COLICA trial. Read more in #EHJ: https://t.co/DRBulWKJ8G ##ESCCongress #inflammation #colchicine #HF @escardio @ESC_Journals

We are told “In era of high sensitivity troponin, unstable angina doesn’t exist and its safe to discharge from ER if HS troponin negative.”Here is an anatomy in patient with “atypical CP with negative HS troponin X3”.